March 3, 2026

Genomic enrichment and functional impact of TP53 and CYLD alterations in recurrent and metastatic HPV-associated head and neck cancer

Puntos clave

Enhanced radiation sensitivity is linked to CYLD loss, while TP53 mutations result in metastatic behavior.
Cisplatin resistance in head and neck cancer may be attributed to gain-of-function mutations in TP53.
Assessment using genomic and functional analysis highlights possible biomarkers for targeted therapy.
Understanding these alterations supports the development of tailored treatment strategies for high-risk HPV positive cases.

Resumen

R/M HPV+ HNSCC is genomically and functionally shaped by 2 axes with therapeutic implications: TP53 gain-of-function mutations promote metastatic phenotypes and cisplatin resistance, while CYLD loss defines an HPV-specific subset with enhanced radiation sensitivity and immune activation. These data support using TP53 and CYLD as predictive biomarkers to guide investigation into precision strategies for systemic therapy choices, p53-targeted/Wee1 strategies, and radiotherapy-immunotherapy combinations in high-risk or R/M HPV+ HNSCC.

Me gusta

Guardar

Me gusta

Guardar

Genomic enrichment and functional impact of TP53 and CYLD alterations in recurrent and metastatic HPV-associated head and neck cancer

Puntos clave

Resumen

Cite This Study